Jeffrey Fowler M MD

Jeffrey Fowler M MD
ProfessorCollege of Medicinefowler.107@osu.edu
M210 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-8737Fax: (614) 293-5877
  • Cancer Control

Current Publications

  • Li Q, Cohn D, Waller A, Backes F, Copeland L, Fowler J, Salani R, O'Malley DOutpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.Gynecol Oncol in press 8/7/2014
  • Eisenhauer EL, Zanagnolo V, Cohn DE, Salani R, O'Malley DM, Sutton G, Callahan MJ, Cobb B, Fowler JM, Copeland LJA phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.Gynecol Oncol 134 262-6 8/1/2014
  • Salani R, Preston MM, Hade EM, Johns J, Fowler JM, Paskett EP, Katz MLSwelling Among Women Who Need Education About Leg Lymphedema: A Descriptive Study of Lymphedema in Women Undergoing Surgery for Endometrial Cancer.Int J Gynecol Cancer in press 7/30/2014
  • Martin DD, Tierney BJ, Eisenhauer EL, Cohn DE, O'Malley DM, Salani R, Copeland LJ, Fowler JM, Backes FJ, Billingsley CCDoes intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Gynecol Oncol in press 7/30/2014
  • Chao AH, McCann GA, Fowler JMAlternatives to commonly used pelvic reconstruction procedures in gynecologic oncology.Gynecol Oncol 134 172-80 7/1/2014
  • Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer ELFeasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study.Int J Gynecol Cancer 24 682-6 5/1/2014
  • Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SXRisk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.J Clin Oncol 32 1210-7 4/20/2014
  • Backes FJ, Fowler JMHysterectomy for the treatment of gynecologic malignancy.Clin Obstet Gynecol 57 115-27 3/1/2014
  • Liang MI, Rosen MA, Rath KS, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DEReducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.Gynecol Oncol 131 508-11 12/1/2013
  • Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23 833-8 6/1/2013
  • Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129 103-6 4/1/2013
  • McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129 135-9 4/1/2013
  • Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR 3rd, Shahin MS, Cantrell LA, Alvarez RD, Gray HJ, Timmins PF 3rd, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RWWe need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.Gynecol Oncol 129 3-4 4/1/2013
  • Greer BE, Boente M, Liang SX, Wenzel L, Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler JPatient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.Gynecol Oncol 128 573-8 3/1/2013
  • Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ 2nd, Van Le L, Trimble CLIs bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.Gynecol Oncol 128 155-9 2/1/2013
  • Brudie LA, Backes FJ, Ahmad S, Zhu X, Finkler NJ, Bigsby GE 4th, Cohn DE, O'Malley D, Fowler JM, Holloway RWAnalysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery.Gynecol Oncol 128 309-15 2/1/2013
  • Backes F, Fowler JMResponse to Dr. Carter's letter to the editor regarding "Short and long term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging".Gynecol Oncol 128 148 1/1/2013
  • Bittoni MA, Fisher JL, Fowler JM, Maxwell GL, Paskett EDAssessment of the effects of severe obesity and lifestyle risk factors on stage of endometrial cancer.Cancer Epidemiol Biomarkers Prev 22 76-81 1/1/2013
  • Backes FJ, Tierney BJ, Eisenhauer EL, Bahnson RR, Cohn DE, Fowler JMComplications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: time to change back?Gynecol Oncol 128 60-4 1/1/2013
  • McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128 44-8 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu